Relay Therapeutics/$RLAY
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Relay Therapeutics
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
Ticker
$RLAY
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
259
ISIN
US75943R1023
Website
RLAY Metrics
BasicAdvanced
$639M
-
-$2.19
1.65
-
Price and volume
Market cap
$639M
Beta
1.65
52-week high
$9.77
52-week low
$1.78
Average daily volume
1.5M
Financial strength
Current ratio
19.963
Quick ratio
19.172
Long term debt to equity
5.718
Total debt to equity
6.54
Profitability
EBITDA (TTM)
-373.071
Gross margin (TTM)
-3,895.92%
Net profit margin (TTM)
-4,341.53%
Operating margin (TTM)
-4,927.05%
Revenue per employee (TTM)
$30,000
Management effectiveness
Return on assets (TTM)
-28.82%
Return on equity (TTM)
-45.46%
Valuation
Price to revenue (TTM)
74.059
Price to book
0.88
Price to tangible book (TTM)
0.88
Price to free cash flow (TTM)
-2.086
Free cash flow yield (TTM)
-47.94%
Free cash flow per share (TTM)
-178.81%
Growth
Revenue change (TTM)
-78.26%
Earnings per share change (TTM)
-16.98%
3-year revenue growth (CAGR)
45.44%
3-year earnings per share growth (CAGR)
-17.19%
What the Analysts think about RLAY
Analyst ratings (Buy, Hold, Sell) for Relay Therapeutics stock.
Bulls say / Bears say
Relay Therapeutics plans to initiate the Phase 3 ReDiscover-2 trial of RLY-2608 combined with fulvestrant in mid-2025 for patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer, indicating progress in its clinical pipeline. (stocktitan.net)
The company reported a median progression-free survival of 11.4 months in second-line patients, with a 39% confirmed overall response rate and a 67% clinical benefit rate, demonstrating promising clinical efficacy. (stocktitan.net)
Relay Therapeutics ended Q4 2024 with $781.3 million in cash and investments, expected to fund operations into the second half of 2027, providing a strong financial foundation for ongoing and future projects. (stocktitan.net)
The company priced a $200 million offering of 28.57 million shares at $7.00 per share, leading to a 17.8% decline in stock price, reflecting potential dilution concerns among investors. (benzinga.com)
Relay Therapeutics' stock reached a new 52-week low of $3.77, indicating potential investor concerns about the company's valuation and future prospects. (techdows.com)
CEO Sanjiv Patel sold 125,000 shares of Relay Therapeutics stock at an average price of $4.80, which may signal a lack of confidence in the company's near-term performance. (techdows.com)
Data summarised monthly by Lightyear AI. Last updated on 11 Jul 2025.
RLAY Financial Performance
Revenues and expenses
RLAY Earnings Performance
Company profitability
RLAY News
AllArticlesVideos
Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors
GlobeNewsWire·4 weeks ago
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June
GlobeNewsWire·1 month ago
Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Relay Therapeutics stock?
Relay Therapeutics (RLAY) has a market cap of $639M as of July 11, 2025.
What is the P/E ratio for Relay Therapeutics stock?
The price to earnings (P/E) ratio for Relay Therapeutics (RLAY) stock is 0 as of July 11, 2025.
Does Relay Therapeutics stock pay dividends?
No, Relay Therapeutics (RLAY) stock does not pay dividends to its shareholders as of July 11, 2025.
When is the next Relay Therapeutics dividend payment date?
Relay Therapeutics (RLAY) stock does not pay dividends to its shareholders.
What is the beta indicator for Relay Therapeutics?
Relay Therapeutics (RLAY) has a beta rating of 1.65. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.